 |
ACS Omega
- WANG Q, Wang H, Lan P, Yang B, et al
Integrative Transcriptomics, Machine Learning, and Molecular Dynamics Reveal
Honghua Longdan (Gentiana rhodantha)?Modulated Therapeutic Targets in Bladder
Cancer.
ACS Omega. 2026;11:17996-18009.
PubMed
Abstract available
Acta Cytol
- XIONG L, Li J, Jin X, Cao X, et al
An Artificial Intelligence-Based Method for Risk Stratification of Urothelial
Carcinoma from Liquid-Based Urine Cytology Whole-Slide Images.
Acta Cytol. 2026;70:211-222.
PubMed
Abstract available
Actas Urol Esp (Engl Ed)
- GUEDES OLIVA P, Jimenez Marrero P, Espino Espino R, Marrero Dominguez R, et al
Urachal adenocarcinoma: Case report, literature review, and therapeutic algorithm
proposal.
Actas Urol Esp (Engl Ed). 2026;50:501916.
PubMed
Abstract available
Anal Chem
- YUAN Y, Xie T, Hu X, Wei X, et al
Aptamer-Based Discovery of Neuropilin-2 as a Potential Biomarker and Therapeutic
Target in Bladder Cancer.
Anal Chem. 2026 Mar 31. doi: 10.1021/acs.analchem.5c07494.
PubMed
Abstract available
Anticancer Res
- SATO T, Sano T, Adachi H, Ikeda Y, et al
Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive
Bladder Cancer Secondary to Radical Nephroureterectomy.
Anticancer Res. 2026;46:2077-2086.
PubMed
Abstract available
- SUGIYAMA Y, Naiki T, Morikawa T, Odagiri K, et al
Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma
Receiving Pembrolizumab.
Anticancer Res. 2026;46:2187-2198.
PubMed
Abstract available
- LIAO CH, Chang WS, Chang SY, Wang YC, et al
Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic
Architecture of Bladder Cancer Risk.
Anticancer Res. 2026;46:1861-1874.
PubMed
Abstract available
- GUTIU AG, Marrah AJ, Voss BB, Cowan BC, et al
Allow Aloe to Do the Work: Aloe vera Constrains Growth of Bladder Cancer Cells
and Modulates Expression of Key Costimulatory Molecules.
Anticancer Res. 2026;46:1883-1892.
PubMed
Abstract available
Biol Direct
- SPEZIALE R, Iacovelli V, Leoni G, Anzillotti L, et al
Plasma metabolomic profiling identifies a metabolic signature for
non-muscle-invasive bladder cancer independent of hematuria.
Biol Direct. 2026 Apr 3. doi: 10.1186/s13062-026-00766.
PubMed
Abstract available
Biomater Adv
- LIU X, Chen L, Lin L, Xie Y, et al
PLZ4@SeD-induced ferroptosis sensitizes bladder cancer to chemotherapy and
immunotherapy.
Biomater Adv. 2026;185:214842.
PubMed
Abstract available
Bioorg Chem
- GRUBA N, Stachurski L, Lesner A
Utility of FRET substrates in bladder cancer diagnosis.
Bioorg Chem. 2026;175:109818.
PubMed
Abstract available
Biosensors (Basel)
- HAO Z, Yue S, Yao L, Gong Y, et al
Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder Cancer.
Biosensors (Basel). 2026;16:171.
PubMed
Abstract available
BJU Int
- HJORT PB, Jensen JB, Ernst A
Long-term outcomes following a 5-year recurrence-free interval in
non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
PubMed
Abstract available
- SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
Reducing complexity in International Bladder Cancer Group intermediate-risk
non-muscle-invasive bladder cancer stratification: a three-factor approach.
BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
PubMed
Abstract available
BMC Cancer
- TANUMA K, Shiga M, Sano K, Hamada K, et al
Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell
mediated antitumor immunity in bladder cancer.
BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
PubMed
- KIM JH, Maeng S, Choi J, Lee CU, et al
The potential antitumor effects of combining intravesical therapy with
recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder
cancer.
BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
PubMed
BMC Urol
- LUO J, Cheng Z, Chen L, Li X, et al
Correlation analysis of HER2 expression with clinicopathological features and
prognosis based on data from 444 patients with urothelial carcinoma.
BMC Urol. 2026;26:86.
PubMed
Abstract available
Cancer Epidemiol Biomarkers Prev
- PRADO S, Ugge H, Vikerfors A, Fall K, et al
Anti-Inflammatory Diet Index (AIDI) and Bladder Cancer Risk by Stage: A 22-Year
Prospective Swedish Cohort Study (1998-2020).
Cancer Epidemiol Biomarkers Prev. 2026.
PubMed
Abstract available
Cancer Imaging
- ZHANG Y, Cai L, Chen Y, Bai R, et al
MRI based unsuperviced clustering on MIBC reveals intratumor heterogeneity
phenotypes and neoadjuvant chemotherapy efficacy.
Cancer Imaging. 2026;26:48.
PubMed
Abstract available
Cancer Med
- GOKHALE P, Zapata LV
Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune
Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis.
Cancer Med. 2026;15:e71777.
PubMed
Abstract available
Cancer Metab
- KAMAL AHM, Putluri V, Gandhi T, Ambati CSR, et al
Leveraging untargeted metabolomics in combination with machine learning to
uncover novel insights into bladder cancer.
Cancer Metab. 2026;14:8.
PubMed
Abstract available
Cancers (Basel)
- NTOUMAS GN, Kougioumtzopoulou A, Desse D, Fragkoulis C, et al
Bladder Preservation with Concurrent Chemoradiotherapy Following Complete
Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder
Cancer: A Review of the Existing Literature.
Cancers (Basel). 2026;18:961.
PubMed
Abstract available
- KIM DK, Jeon J, Kwon JK, Bang S, et al
Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus
Calmette-Guerin for Bladder Cancer: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2026;18:990.
PubMed
Abstract available
- LILLESAND M, Austdal M, Mroz J, Skaland I, et al
Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG
Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2026;18:938.
PubMed
Abstract available
- UGRINOVSKI D, Saidi S, Stankov V, Ambardjieva M, et al
Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic
Subgroups in Urothelial Bladder Cancer.
Cancers (Basel). 2026;18:1026.
PubMed
Abstract available
Cardiovasc Interv Ther
- KUSUMOTO H, Inoue M, Shishikura D, Kanzaki Y, et al
Myocardial infarction due to nonbacterial thrombotic endocarditis in a patient
with advanced bladder cancer.
Cardiovasc Interv Ther. 2026 Mar 31. doi: 10.1007/s12928-026-01256.
PubMed
Cell Death Differ
- HUA X, Huang M, Deng X, Xu J, et al
Correction: The inhibitory effect of compound ChlA-F on human bladder cancer cell
invasion can be attributed to its blockage of SOX2 protein.
Cell Death Differ. 2026 Apr 2. doi: 10.1038/s41418-026-01721.
PubMed
Chin Med J (Engl)
- OU J, Ni K, Song H, Li G, et al
The hidden burden: Clinical impact of incidental prostate cancer in bladder
cancer patients.
Chin Med J (Engl). 2026 Mar 30. doi: 10.1097/CM9.0000000000004031.
PubMed
Clin Exp Med
- CAO Y, Li C, Hua Y, Wu T, et al
Multi-omics identification of a programmed cell death-related signature and
potential target P4HB for bladder cancer based on a 101-combination machine
learning and experimental validation.
Clin Exp Med. 2026;26:214.
PubMed
Clin Genitourin Cancer
- RIVES H, Fredette J, Anari F, Ghatalia P, et al
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose
Reduction in Metastatic Bladder Cancer.
Clin Genitourin Cancer. 2026 Mar 3:102525. doi: 10.1016/j.clgc.2026.102525.
PubMed
Abstract available
Curr Oncol
- SOUTH N, Mihai IM, Wang V, Agoumi M, et al
Urachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases.
Curr Oncol. 2026;33:153.
PubMed
Abstract available
- VENTO J, Zhang T, Lotan Y, Woldu S, et al
Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the
Perioperative Management of Muscle-Invasive Bladder Cancer.
Curr Oncol. 2026;33:162.
PubMed
Abstract available
- MARWAHA A, Sambhi R, Fernandes R
Dermatomyositis as a Paraneoplastic Syndrome of Metastatic Urothelial Carcinoma.
Curr Oncol. 2026;33:176.
PubMed
Abstract available
Curr Opin Urol
- ALIAGA A, Avila C, Fernandez MI
Navigating bladder preservation in Bacillus Calmette-Guerin-unresponsive disease:
how much risk is too much?
Curr Opin Urol. 2026;36:235-243.
PubMed
Abstract available
- AHMAD A, Lepiarczyk O, Birtle AJ
Personalised medicine in urothelial carcinoma: where do we stand and what is the
way to go?
Curr Opin Urol. 2026;36:250-256.
PubMed
Abstract available
- LEE YHA, Wong CM, Liu AQ, Teoh JY, et al
The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of
novel therapeutic agents.
Curr Opin Urol. 2026;36:244-249.
PubMed
Abstract available
Eur Radiol
- BONATTI M, Valletta R, D'Erme L, Dolciami M, et al
Preoperative staging of cervical cancer: time to shift from cystoscopy to MRI.
Eur Radiol. 2025 Oct 4. doi: 10.1007/s00330-025-12039.
PubMed
Abstract available
Expert Rev Anticancer Ther
- ZHANG Y, Yan R, Wang H, Man J, et al
From macroscopic clearance to molecular eradication: paradigm shift and future
perspectives in the detecting of residual lesions after transurethral resection
of bladder tumors.
Expert Rev Anticancer Ther. 2026;26:463-477.
PubMed
Abstract available
Front Immunol
- OLUWATOLA O, Bazargan S, Irrera P, Chang D, et al
Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits
antitumor responses in bladder cancer.
Front Immunol. 2026;17:1706250.
PubMed
Abstract available
- AVILA-NIETO C, Jung G, Salih HR, Hagelstein I, et al
Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple
negative breast and bladder cancer.
Front Immunol. 2026;17:1794705.
PubMed
Abstract available
- KNEZEVIC M, Tomaskovic I, Murgic J, Vrhovec B, et al
Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and
PD-L1.
Front Immunol. 2026;17:1777409.
PubMed
Abstract available
Front Med (Lausanne)
- URSO L, Feletti F, Lancia F, Canella F, et al
Diagnostic accuracy of (18)F-FDG PET/CT in muscle-invasive bladder cancer:
rationale and design of the MIBC-PET study.
Front Med (Lausanne). 2026;13:1792243.
PubMed
Abstract available
Front Oncol
- RUSSO F, Tripodi L, Caldora F, Pandolfo SD, et al
Identification of a weighted urinary microbial signature for bladder cancer
discrimination.
Front Oncol. 2026;16:1784501.
PubMed
Abstract available
- LIU R, Wang J
Recent advances in immunotherapy for bladder cancer: mechanisms, clinical
applications, and future perspectives.
Front Oncol. 2026;16:1786965.
PubMed
Abstract available
Front Pharmacol
- ZHUANG J, Wang H, Chen Z, Wang J, et al
Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via
autophagy flux inhibition.
Front Pharmacol. 2026;17:1676788.
PubMed
Abstract available
Front Urol
- SHIBAMORI K, Hashimoto K, Okabe K, Maehana T, et al
Absence of bladder cancer cells in surgical smoke from robot-assisted radical
cystectomy: a prospective study.
Front Urol. 2026;6:1714844.
PubMed
Abstract available
Gene
- BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
Corrigendum to "Role of myeloid-derived suppressor cells in bladder cancer and
targeted therapeutic strategies" [Gene 970 (2025) 149772].
Gene. 2026 Mar 28:150129. doi: 10.1016/j.gene.2026.150129.
PubMed
Hinyokika Kiyo
- SATO T, Hayata N, Hida T, Miura T, et al
[A Case of Asymptomatic Paraganglioma of the Bladder].
Hinyokika Kiyo. 2026;72:1-6.
PubMed
Abstract available
In Vitro Cell Dev Biol Anim
- YI L, Chen Q, Zeng M, Xiao Z, et al
Elevated intravesical pressure promotes circulating tumor cell release in an
orthotopic mouse model of bladder cancer.
In Vitro Cell Dev Biol Anim. 2026 Mar 30. doi: 10.1007/s11626-026-01176.
PubMed
Abstract available
Indian J Pathol Microbiol
- TRIPATHY SR, Ayyanar P, Das DK, Barik SK, et al
Plasmacytoid subtype of urothelial carcinoma - Report of two rare cases and
unusual features.
Indian J Pathol Microbiol. 2026;69:174-177.
PubMed
Abstract available
Infect Drug Resist
- YAN YC, Guo Q, Xu J, Wei Z, et al
Marked Non-Infectious Elevation of Procalcitonin in a Hemodialysis Patient with
Bladder Cancer: A Case Report.
Infect Drug Resist. 2026;19:569356.
PubMed
Abstract available
Int J Mol Sci
- SINGH SP, Liu R, Yan F, Tang Q, et al
Galactokinase 1 Inhibition-Induced Cell Cycle Arrest and Apoptosis in Bladder
Cancer Cells Is Associated with AKT Signaling Downregulation.
Int J Mol Sci. 2026;27:2911.
PubMed
Abstract available
- BAI J, Yu H, Hu C, Ma Y, et al
Integrating Multi-Omics Atlas to Uncover Genetic and Epigenetic Mechanisms and
Reveal Cell State Evolution Across Ecotypes in Male Urological Cancers.
Int J Mol Sci. 2026;27:2712.
PubMed
Abstract available
Int J Urol
- USUI A, Hara T, Oka S, Sakaguchi K, et al
Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With
Non-Muscle Invasive Bladder Cancer: Real-World Incidence and Concomitant
Medication Effects.
Int J Urol. 2026;33:e70448.
PubMed
Abstract available
- FUJITA N
Editorial Comments to "Palliative Intra-Arterial Chemotherapy Without
Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A
Single-Center Retrospective Comparison With Radical Cystectomy and Best
Supportive Care".
Int J Urol. 2026;33:e70452.
PubMed
J Cancer Res Ther
- JHA T, Ahuja A, Sharma M, Goel HK, et al
Uncommon but aggressive: A case series on urinary bladder neuroendocrine
carcinomas.
J Cancer Res Ther. 2026;22:196-199.
PubMed
Abstract available
J Exp Clin Cancer Res
- HE Y, Gong Y, Wu Y, He S, et al
RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated
regulation of ZO2.
J Exp Clin Cancer Res. 2026 Mar 30. doi: 10.1186/s13046-026-03684.
PubMed
- FRASCOLLA C, Mastroianni R, Macedo-Silva C, De Menna M, et al
Bridging phenotype and function in bladder cancer using immuno-competent
organoids and ex vivo drug screening.
J Exp Clin Cancer Res. 2026 Apr 1. doi: 10.1186/s13046-026-03701.
PubMed
J Mol Cell Biol
- XIAO Y, Yang J, Sun M, Li Y, et al
The tumor-associated fibroblasts regulate urothelial carcinoma progression.
J Mol Cell Biol. 2026;17:mjaf032.
PubMed
Abstract available
J Mol Histol
- CHI Q, Xu H, Li H, Ma G, et al
Cx43 modulates malignant phenotypes in bladder cancer cells via the
c-Src/PTEN/FAK axis.
J Mol Histol. 2026;57:129.
PubMed
Abstract available
J Natl Compr Canc Netw
- OTANI Y, Otani K, Rodden D, Lemieux M, et al
PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder
Cancer After Bladder-Sparing Trimodality Therapy.
J Natl Compr Canc Netw. 2026;24.
PubMed
- SU ZT, Florissi IS, Geller AE, Johnson Iii BA, et al
Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant
Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.
J Natl Compr Canc Netw. 2026 Mar 19:1-7. doi: 10.6004/jnccn.2025.7129.
PubMed
Abstract available
J Pathol Clin Res
- OLAH C, Juhasz D, Varadi M, Reis H, et al
Molecular subtype concordance and metastatic patterns in muscle-invasive bladder
cancer.
J Pathol Clin Res. 2026;12:e70088.
PubMed
Abstract available
Jpn J Radiol
- XIAO W, Zhang Z, Wang Y, Zhang W, et al
Enhancing the performance of BP-MRI VI-RADS in detecting muscle-invasive bladder
cancer: the potential role of supplementary quantitative parameters.
Jpn J Radiol. 2026 Mar 27. doi: 10.1007/s11604-026-01970.
PubMed
Abstract available
Lasers Med Sci
- CHEN D, Zhou Z, Wei G, Zhang F, et al
Perioperative and oncological outcomes of thulium laser-ERBT versus conventional
TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.
Lasers Med Sci. 2026;41:63.
PubMed
Abstract available
medRxiv
- MAGNANI CJ, D'Andrea VD, Barros GG, Qian Z, et al
Clinical and genomic profiling of early-onset bladder cancer identifies key
alterations and therapeutic targets.
medRxiv [Preprint]. 2026 Mar 24:2025.01.10.25320337.
PubMed
Abstract available
Mol Med Rep
- QIAO Q, Guo R, Sun Z, Shi Y, et al
Polyphyllin II regulates ROS levels and promotes ferroptosis in bladder cancer
cells.
Mol Med Rep. 2026;33:148.
PubMed
Abstract available
Mol Pharm
- DURRANI FA, Cacaccio J, Potter W, Dukh M, et al
Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2
Inhibitor in Treating Bladder Cancer.
Mol Pharm. 2026 Apr 1. doi: 10.1021/acs.molpharmaceut.5c01678.
PubMed
Abstract available
Nurs Open
- ZHOU L, Chen Y, Yuan X, Guo F, et al
Experiential Aspects in Patients With Permanent Urostomy Following Bladder Cancer
Surgery: Meta-Synthesis of Qualitative Studies.
Nurs Open. 2026;13:e70517.
PubMed
Abstract available
Oncol Rep
- WANG X, Chen E, Yang X, Wang Y, et al
[Expression of Concern] 5?Azacytidine inhibits the proliferation of bladder
cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene.
Oncol Rep. 2026;55:103.
PubMed
Abstract available
Oncol Res
- GIORGIONE R, Grasso D, Gambale E, Scolari F, et al
Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and
Monitoring during Platinum-Based Therapy.
Oncol Res. 2026;34:1.
PubMed
Abstract available
- SUN S, Zhang J, Zheng Z, Hao Y, et al
PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune
Microenvironment Remodeling.
Oncol Res. 2026;34:30.
PubMed
Abstract available
Oncol Rev
- YI X, Zhao Z, Li J
Development and validation of a risk prediction model for chemical cystitis in
patients with non-muscle-invasive bladder cancer undergoing intravesical
instillation.
Oncol Rev. 2026;20:1791893.
PubMed
Abstract available
PLoS One
- CHEN J, Li B, Gan Y, Li P, et al
TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to
immunotherapy in urothelial bladder cancer.
PLoS One. 2026;21:e0346131.
PubMed
Abstract available
Radiol Med
- BORRELLI A, Novelli S, Messina E, Laschena L, et al
AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy
outcomes in muscle-invasive bladder cancer.
Radiol Med. 2026 Mar 31. doi: 10.1007/s11547-026-02203.
PubMed
Abstract available
Res Rep Urol
- HEMMATI GHAVSHOUGH M, Fu MZ, Islam R, Patel D, et al
Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder
Cancer: A Narrative Review Across Risk Groups.
Res Rep Urol. 2026;18:584499.
PubMed
Abstract available
Sci Rep
- GUO X, Wang S, Ma Y, Chen Y, et al
Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk
non-muscle invasive bladder cancer.
Sci Rep. 2026 Apr 2. doi: 10.1038/s41598-026-43393.
PubMed
- KABUS M, Aumiller M, Ruhm A, Pongratz T, et al
Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach
against bladder cancer cells.
Sci Rep. 2026;16:11228.
PubMed
Abstract available
Semin Oncol
- LIU Y, Zhao T, Shi R, Xie Y, et al
Cancer-associated fibroblasts in bladder cancer: Immunosuppressive mechanisms and
therapeutic targeting.
Semin Oncol. 2026;53:152483.
PubMed
Abstract available
Urol Int
- WANG Q, Lin Q, Li L, Wei W, et al
The Predictive Value of Urinary Twist1 Methylation and VI-RADS Score for Residual
Tumor before Repeat Transurethral Resection of Bladder Tumor in NMIBC Patients.
Urol Int. 2026;110:114-124.
PubMed
Abstract available
Urol Oncol
- PATEL KN, Yalla P, Panchal H, Pandya SJ, et al
Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive
bladder cancer?
Urol Oncol. 2026 Mar 28:111080. doi: 10.1016/j.urolonc.2026.111080.
PubMed
Abstract available
FAQ
